ArticleNature nanotechnology2014
Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils.
Article in Nature nanotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 294 citations in OpenAlex.
- PDHA1 Hyperactivation-Mediated Glucose Metabolism Reprogramming Fuels Neutrophil NETosis and Promotes Acute Lung Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Research Advances on Organelle-Targeted Drug Delivery Systems for the Treatment of Brain Tumors and Central Nervous System Inflammation.Pharmaceutics · 2026Review
- Cell-inspired dual-tandem catalytic nanoreactors drive targeted hearing protection.Nature communications · 2026Article
- Targeted Delivery of Specialized Pro-Resolving Mediators (SPMs) for Improved Treatments of Inflammatory Diseases and Cancer.Pharmaceutics · 2026Review
- Immunomodulatory Nanomaterials: Design Strategies, Mechanisms, Biomedical Applications, and Future Perspectives.Biomedicines · 2026Review
- Harnessing Targeted Polymerized Salicylic Acid Particles to Mitigate Neutrophil-Driven Inflammation.ACS biomaterials science & engineering · 2026Article
- Bioresponsive immunomodulator nanocomplex for selective immunoengineering in metastatic lymph nodes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- From Circulation to Regeneration: Blood Cell Membrane-Coated Nanoparticles as Drug Delivery Platform for Immune-Regenerative Therapy.Pharmaceutics · 2026Review
- Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment.International journal of nanomedicine · 2026Review
- Targeting a specific subset of neutrophils to mitigate cardiac reperfusion injury.Research square · 2025Article
- Recent advances in albumin-based nanoparticle drug delivery systems for intestinal disease treatment.International journal of pharmaceutics: X · 2025Review
- Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases.Advanced healthcare materials · 2025Review
- Advanced nanotherapies for precision treatment of inflammatory lung diseases.Bioactive materials · 2025Review
- Harnessing smart nanomaterials to reprogram neutrophil plasticity in immune modulation.Journal of nanobiotechnology · 2025Review
- Spatiotemporal regulation of neutrophil heterogeneity in health and disease.Human molecular genetics · 2025Review
- Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles.Drug delivery and translational research · 2025Article
- Rod-shaped Polymerized Salicylic Acid Particles Modulate Neutrophil Transendothelial Migration in Acute Inflammation.Advanced healthcare materials · 2025Article
- Neuroimmune interactions: The bridge between inflammatory bowel disease and the gut microbiota.Clinical and translational medicine · 2025Review
- The novel GSDMD inhibitor GI-Y2 exerts antipyroptotic effects to reduce atherosclerosis.Clinical and translational medicine · 2025Article
- Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory diseases such as acute lung injury and ischaemic tissue injury are caused by the adhesion of a type of white blood cell--polymorphonuclear neutrophils--to the lining of the circulatory system or vascular endothelium and unchecked neutrophil transmigration. Nanoparticle-mediated targeting of activated neutrophils on vascular endothelial cells at the site of injury may be a useful means of directly inactivating neutrophil transmigration and hence mitigating vascular inflammation. Here, we report a method employing drug-loaded albumin nanoparticles, which efficiently deliver drugs into neutrophils adherent to the surface of the inflamed endothelium. Using intravital microscopy of tumour necrosis factor-α-challenged mouse cremaster post-capillary venules, we demonstrate that fluorescently tagged albumin nanoparticles are largely internalized by neutrophils adherent to the activated endothelium via cell surface Fcɣ receptors. Administration of albumin nanoparticles loaded with the spleen tyrosine kinase inhibitor, piceatannol, which blocks 'outside-in' β2 integrin signalling in leukocytes, detached the adherent neutrophils and elicited their release into the circulation. Thus, internalization of drug-loaded albumin nanoparticles into neutrophils inactivates the pro-inflammatory function of activated neutrophils, thereby offering a promising approach for treating inflammatory diseases resulting from inappropriate neutrophil sequestration and activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.